Pay in 4 interest-free payments of $5.80 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
A phase 3b, randomized, multicenter, controlled study of mirikizumab and placebo or mirikizumab concomitantly administered with tirzepatide in adult participants with moderately to severely active ulcerative colitis and obesity or overweight
Highly specific epigenome editing by CRISPRCas9 repressors for silencing of distal regulatory elements
Mol Cell Biochem 423(12):115127
Nature 440(7082):352357
Never begin, stop, or modify peptide therapy without medical guidance
US$ 27.96
US$ 27.56
US$ 23.66
US$ 20.37
US$ 28.91
US$ 20.17
US$ 22.78
US$ 29.03
